DaVita Inc. (NYSE:DVA) Shares Sold by Hennessy Advisors Inc.

Hennessy Advisors Inc. reduced its position in DaVita Inc. (NYSE:DVA) by 10.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,800 shares of the company’s stock after selling 7,500 shares during the period. Hennessy Advisors Inc. owned about 0.08% of DaVita worth $10,065,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of DaVita by 22.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock worth $666,000 after purchasing an additional 800 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in shares of DaVita during the first quarter worth approximately $989,000. Fifth Third Bancorp boosted its holdings in shares of DaVita by 5.0% during the first quarter. Fifth Third Bancorp now owns 4,274 shares of the company’s stock worth $654,000 after purchasing an additional 204 shares during the period. CX Institutional boosted its holdings in shares of DaVita by 11.7% during the first quarter. CX Institutional now owns 1,614 shares of the company’s stock worth $247,000 after purchasing an additional 169 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of DaVita during the first quarter worth approximately $846,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DVA has been the subject of several research reports. Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a report on Monday, May 19th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita has a consensus rating of “Hold” and an average target price of $164.50.

DaVita Price Performance

Shares of DaVita stock opened at $135.93 on Friday. The firm has a fifty day simple moving average of $141.36 and a 200-day simple moving average of $151.18. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60. The stock has a market capitalization of $10.26 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 1.07 and a beta of 1.11.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same period in the previous year, the company earned $2.26 earnings per share. DaVita’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.